A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
← catalyst calendarNCT07430306 · readout in 890 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON plc.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
245estimated
Sites
103
Countries
Canada, France, Germany +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-13 | actual | When the study began enrolling |
| Primary completion | 2029-01-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-26 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Systemic Lupus Erythematosus
Intervention
- Drug: Anifrolumab — also filed as Saphnelo
Primary outcome
what the primary-completion date above is the date OFAttainment of DORIS remission
measured At Week 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed